# Identifying AOD-9604 in seized material

> Unknown preparations | The Peptide Program — The Peptide Program examines AOD-9604 identified in seized preparations, alongside analytical methods for detecting small peptides in sports drug testing.

**Chemical analysis / A case report**

An unknown preparation gives chemical analysis a different starting sample from the urine used in the screening method.

## The identification case

In a [2014 case report](https://pubmed.ncbi.nlm.nih.gov/24976118/), investigators identified and characterised AOD-9604 in unknown pharmaceutical preparations seized by Belgian authorities. The report documents this growth-hormone fragment in material encountered outside approved channels.

The switch of sample material sharpens this comparison. Here the investigators faced an unknown pharmaceutical preparation; the urine screen discussed on the home page used urine and covered named peptide targets. The kind of sample belongs in the account of each method.

The case establishes AOD-9604’s identity in the seized material. It supplies no reason to carry the urine panel’s detection-limit range over to that preparation.

![An illustrated analytical balance holding a plain weighing boat beside a closed glass sample dish on an ivory laboratory bench.](images/unknown-sample-balance.webp)

*An imagined analytical still life about establishing chemical identity, with no sample or setting taken from the case report.*

## AOD-9604 within sports drug testing

The [2016 screening method](https://pubmed.ncbi.nlm.nih.gov/26578461/) included AOD-9604 among low-molecular-mass peptides examined through direct urine injection, liquid chromatography and ion mobility mass spectrometry. The [2017 mass-spectrometry review](https://pubmed.ncbi.nlm.nih.gov/26213263/) places peptidic drugs including AOD-9604 within the scope of modern sports drug testing.

Direct urine injection is an appealingly concrete phrase. The 2016 method reported detection limits of 50-500 pg/mL for its peptide panel. That range describes the search performed with that method; the wider review supplies context for sports drug testing, rather than a universal cutoff for every screen.

The cited analytical claims describe methods and their scope; a prevalence estimate would need observations designed to establish prevalence.

## The sample and the panel

The [in vitro and rodent metabolic studies](https://pubmed.ncbi.nlm.nih.gov/11146367/) and the [human oral tolerability report](https://www.jofem.org/index.php/jofem/article/view/157/194) give research background for AOD-9604, one of the urine screen’s targets.

The sample and panel are where this analytical question becomes specific. A case report identifying AOD-9604 in seized material and a urine screen covering it are useful at their stated scope. Their shared target does not make the reported urine detection limits apply to both kinds of material.

The [fat-metabolism essay](/fat-metabolism) follows one set of biological experiments. The [human trial record](/human-trials) concerns a different population and purpose.

---

Here I pursue the published AOD-9604 research from chemical identification to human tolerability; The Peptide Program is an editorial site, with no treatment service or medical advice.